456 related articles for article (PubMed ID: 24370903)
1. Prognostic significance of targetable angiogenic and growth factors in patients undergoing resection for gastric and gastroesophageal junction cancers.
Park DJ; Yoon C; Thomas N; Ku GY; Janjigian YY; Kelsen DP; Ilson DH; Goodman KA; Tang LH; Strong VE; Coit DG; Yoon SS
Ann Surg Oncol; 2014 Apr; 21(4):1130-7. PubMed ID: 24370903
[TBL] [Abstract][Full Text] [Related]
2. Extranodal metastasis is a powerful prognostic factor in patients with adenocarcinoma of the esophagogastric junction.
Zhang HD; Tang P; Duan XF; Chen CG; Ma Z; Gao YY; Zhang H; Yu ZT
J Surg Oncol; 2013 Dec; 108(8):542-9. PubMed ID: 24018956
[TBL] [Abstract][Full Text] [Related]
3. Lymphadenectomy for adenocarcinoma of the gastroesophageal junction (GEJ): impact of adequate staging on outcome.
Barbour AP; Rizk NP; Gonen M; Tang L; Bains MS; Rusch VW; Coit DG; Brennan MF
Ann Surg Oncol; 2007 Feb; 14(2):306-16. PubMed ID: 17091329
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction.
Phillips BE; Tubbs RR; Rice TW; Rybicki LA; Plesec T; Rodriguez CP; Videtic GM; Saxton JP; Ives DI; Adelstein DJ
Dis Esophagus; 2013 Apr; 26(3):299-304. PubMed ID: 22676551
[TBL] [Abstract][Full Text] [Related]
5. Role of repeat staging laparoscopy in locoregionally advanced gastric or gastroesophageal cancer after neoadjuvant therapy.
Cardona K; Zhou Q; Gönen M; Shah MA; Strong VE; Brennan MF; Coit DG
Ann Surg Oncol; 2013 Feb; 20(2):548-54. PubMed ID: 22941159
[TBL] [Abstract][Full Text] [Related]
6. Expression of vascular endothelial growth factor C correlates with lymphatic vessel density and prognosis in human gastroesophageal junction carcinoma.
Yang LP; Fu LC; Guo H; Xie LX
Onkologie; 2012; 35(3):88-93. PubMed ID: 22414971
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological features and prognostic factors of adenocarcinoma of the esophagogastric junction according to Siewert classification: experiences at a single institution in Japan.
Hosokawa Y; Kinoshita T; Konishi M; Takahashi S; Gotohda N; Kato Y; Daiko H; Nishimura M; Katsumata K; Sugiyama Y; Kinoshita T
Ann Surg Oncol; 2012 Feb; 19(2):677-83. PubMed ID: 21822549
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Survival in Patients with Gastroesophageal Junction Cancer Treated with Preoperative Therapy: Do Thoracic and Abdominal Approaches Differ?
Kneuertz PJ; Hofstetter WL; Chiang YJ; Das P; Blum M; Elimova E; Mansfield P; Ajani J; Badgwell B
Ann Surg Oncol; 2016 Feb; 23(2):626-32. PubMed ID: 26564243
[TBL] [Abstract][Full Text] [Related]
9. C-reactive protein/albumin ratio is a poor prognostic factor of esophagogastric junction and upper gastric cancer.
Kudou K; Saeki H; Nakashima Y; Kamori T; Kawazoe T; Haruta Y; Fujimoto Y; Matsuoka H; Sasaki S; Jogo T; Hirose K; Hu Q; Tsuda Y; Kimura K; Ando K; Oki E; Ikeda T; Maehara Y
J Gastroenterol Hepatol; 2019 Feb; 34(2):355-363. PubMed ID: 30119141
[TBL] [Abstract][Full Text] [Related]
10. Comparison between site N-category and number N-category for nodal staging in carcinoma of the gastroesophageal junction: our experience and literature review.
Aurello P; D'Angelo F; Nigri G; Bellagamba R; Cicchini C; Ruzzetti R; Ramacciato G
Am Surg; 2006 Feb; 72(2):118-23. PubMed ID: 16536239
[TBL] [Abstract][Full Text] [Related]
11. [Surgical treatment of gasto-esophageal junction adenocarcinoma: long-term results of a single Italian centre].
Pedrazzani C; Pasini F; Giacopuzzi S; Bernini M; Ruzzenente A; Festini M; Tomasi I; Cristadoro L; de Manzoni G
G Chir; 2004 Oct; 25(10):325-33. PubMed ID: 15756954
[TBL] [Abstract][Full Text] [Related]
12. A Multi-Institutional Study Comparing the Use of the American Joint Committee on Cancer 7th Edition Esophageal
Adeshuko FA; Squires MH; Poultsides G; Pawlik TM; Weber SM; Schmidt C; Votanopoulos K; Fields RC; Maithel SK; Cardona K
Am Surg; 2017 Jan; 83(1):82-89. PubMed ID: 28234131
[TBL] [Abstract][Full Text] [Related]
13. [Effect of number of metastatic lymph nodes and metastatic lymph node ratio on the prognosis in patients with adenocarcinoma of the esophagogastric junction after curative resection].
Zhang H; Chen C; Yue J; Ma M; Ma Z; Yu Z
Zhonghua Zhong Liu Za Zhi; 2014 Feb; 36(2):141-6. PubMed ID: 24796465
[TBL] [Abstract][Full Text] [Related]
14. [Comparison of clinicopathological features and prognosis between adenocarcinoma of esophagogastric junction and adenocarcinoma of gastric antrum].
Zhu Z; Wang Y; Li F; Gao J; Han B; Wang R; Xue Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Feb; 22(2):149-155. PubMed ID: 30799537
[TBL] [Abstract][Full Text] [Related]
15. Factors predicting survival in patients with proximal gastric carcinoma involving the esophagus.
Zhang YF; Shi J; Yu HP; Feng AN; Fan XS; Lauwers GY; Mashimo H; Gold JS; Chen G; Huang Q
World J Gastroenterol; 2012 Jul; 18(27):3602-9. PubMed ID: 22826627
[TBL] [Abstract][Full Text] [Related]
16. Staging laparoscopy in gastroesophageal and gastric adenocarcinoma: first experience from Pakistan.
Bhatti AB; Haider S; Khattak S; Syed AA
Indian J Cancer; 2014; 51(1):15-7. PubMed ID: 24947089
[TBL] [Abstract][Full Text] [Related]
17. Serum VEGF-A and Tumor Vessel VEGFR-2 Levels Predict Survival in Caucasian but Not Asian Patients Undergoing Resection for Gastric Adenocarcinoma.
Park DJ; Seo AN; Yoon C; Ku GY; Coit DG; Strong VE; Suh YS; Lee HS; Yang HK; Kim HH; Yoon SS
Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S1508-15. PubMed ID: 26259755
[TBL] [Abstract][Full Text] [Related]
18. [Clinical and pathological prognostic factors for cancers of the esophagogastric junction].
Schmidt SC; Schlechtweg N; Veltzke-Schlieker W; Thuss-Patience P; Pratschke J; Neuhaus P; Schumacher G
Zentralbl Chir; 2009 Sep; 134(5):455-61. PubMed ID: 19757346
[TBL] [Abstract][Full Text] [Related]
19. Safety, efficacy, and long-term follow-up evaluation of perioperative epirubicin, Cisplatin, and capecitabine chemotherapy in esophageal resection for adenocarcinoma.
van der Sluis PC; Ubink I; van der Horst S; Boonstra JJ; Voest EE; Ruurda JP; Borel Rinkes IH; Wiezer MJ; Schipper ME; Siersema PD; Los M; Lolkema MP; van Hillegersberg R
Ann Surg Oncol; 2015 May; 22(5):1555-63. PubMed ID: 25564156
[TBL] [Abstract][Full Text] [Related]
20. Serum level of hepatocyte growth factor is a novel marker of predicting the outcome and resistance to the treatment with trastuzumab in HER2-positive patients with metastatic gastric cancer.
Takahashi N; Furuta K; Taniguchi H; Sasaki Y; Shoji H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Hamaguchi T; Shimada Y; Yamada Y
Oncotarget; 2016 Jan; 7(4):4925-38. PubMed ID: 26716644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
